The Conversation (0)
Bavarian Nordic A/S today announced its financial calendar for the year 2017. Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company’s live virus vaccine platform.
COPENHAGEN, Denmark, September 13, 2016 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced its financial calendar for the year 2017.
| March 15, 2017 | 2016 Annual Report |
| April 25, 2017 | Annual General Meeting |
| May 4, 2017 | First quarterly report (Q1) for the three-month period ended 31 March 2017 |
| August 25, 2017 | Half-year report (Q2) for the six-month period ended 30 June 2017 |
| November 8, 2017 | Third quarterly report (Q3) for the nine-month period ended 30 September 2017 |
Pursuant to Article 12 of the Articles of Association, shareholders who wish to submit a request for proposals for consideration at the Annual General Meeting must lodge this with the Company no later than Wednesday, March 15, 2017.
Moreover, it should be noted that Bavarian Nordic in a period of two weeks before planned publication of quarterly reports (silent periods), will not comment specifically on developments or financial issues and expectations.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company’s live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
Company Announcement no. 26 / 2016